Additionally , subgroup analyses of patients with ( @ ) multiple tumors or a single tumor @ cm ; and ( @ ) hepatitis B or C revealed that administering PI-@ at @ mg/d conferred the most significant survival advantage ( @ % improvement in disease-free survival , P = @ ) for patients with both risk factors for recurrence .